A new drug for advanced prostate cancer that has stopped responding to treatment
Part of Cancer, Kidney & urinary clinical trials.
This early-phase trial tests a new study drug called ACE-232 for men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It aims to see if the drug is safe and may help slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic prostate cancer that is still growing even when your testosterone is very low (castration-resistant).
- You have already tried at least one hormone therapy and one chemotherapy, but the cancer kept growing or you had bad side effects.
- You are generally healthy enough to walk and do light work (ECOG 0 or 1).
- Your doctor expects you to live at least 6 more months.
- You do not have cancer spread to your brain or spinal cord, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
This trial tests an experimental new drug (GSK5471713) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It is for people who have already tried certain hormone treatments and chemotherapy.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests two investigational drugs together for men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This study tests a combination of two new investigational drugs for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drugs aim to help your immune system fight the cancer cells.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.